Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy

NCT ID: NCT01038258

Last Updated: 2012-07-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2013-04-30

Brief Summary

A PET scan drop less than 20% in SUVs or below a certain absolute SUV value after the first course of neoadjuvant chemotherapy can predict pathological response, and could in the future lead to an early surgical intervention.

Detailed Description

The use of neo-adjuvant systemic therapy in women recently diagnosed with breast cancer is growing in popularity based on its proven benefit (1). Pre-operative chemotherapy not only can assist in regards to breast conservation therapy (2) but data suggest prognostic benefits in those subset of patient's obtaining complete pathological response (3,4) .

It is imperative for clinicians to detect as early as possible those patients likely to obtain the desired clinical and /or pathologic response, thus identifying those patients who don't benefit from the first line neoadjuvant treatment so that their treatment can be modified accordingly.

Response to treatment based on clinical data or structural imaging, usually requires several chemotherapeutic cycles to establish degree of effectiveness (5). Lately, FDG-PET/CT has been used in different types of neoplasms, breast cancer among them, to establish early response to treatment (6,7). Recent data has established the usefulness of metabolic analysis via FDG-PET, in separating subgroups of chemotherapy. For such analytical approach, sequential estimation of SUVs (Standardized Uptake Value) have been measured along the duration of the treatment. Reduction in SUVs presumes adequate response to treatment (8), while little or no change in metabolic activity presumes sub-optimal response .

However, no definite consensus has been established in regards to what degree of metabolic response is predictive of the desired clinical benefit, particularly early in the treatment . Establishing such criteria could potentially serve as a guideline for monitoring neoadjuvant treatment. Schelling et al, was able to separate a group of patients that eventually showed either progression of the disease or no clinical response as early as the first course of chemotherapy.

The aim of our study is to establish a simple formula using FDG-PET/CT, as early as the first course of chemotherapy, to stratify patients undergoing neoadjuvant chemotherapy for recently diagnosed breast cancer. Those who will benefit from continuing the same treatment will be regarded as responders versus non-responders, which are those in need of changing strategy.

The primary goal of this study is to correlate the results of FDG-PET/CT performed 15 days after the first course of chemotherapy versus those of clinical assessment and breast MRI obtained after the 3rd course of chemotherapy. At that time, a clinical decision on which therapeutic path to be followed will be made.

Conditions

Invasive Ductal Carcinoma; Lobular Breast Carcinoma; Inflammatory Breast Carcinoma

Keywords

neoadjuvant chemotherapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

No arms

No arms

Group Type: OTHER

PET scan after course 1 and surgery after 8 courses

Intervention Type: PROCEDURE

PET scan and surgery

Interventions

PET scan after course 1 and surgery after 8 courses

PET scan and surgery

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Recently diagnosed breast carcinoma that will receive neoadjuvant chemotherapy based on: Tumors size greater than 2 cms; Locally advanced tumors, Tumors close to or invading chest wall or areola and/or Inflammatory Breast cancer.
• 18 years of age.
• Available for follow-up visits
• Able to comply with study requirements.
• Have signed an IRB approved written informed consent form

Exclusion Criteria

• Any significant medical or psychiatric illness, which would prevent the patient from giving informed consent or following the study procedures.
• Pregnant and Nursing women.
• No restriction will be placed on the chemotherapy regimen used although we expect that most patients will receive Anthracycline based regimens.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sononuclear

UNKNOWN

Sponsor Role: collaborator

Auxilio Mutuo Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Fernando Cabanillas

Hematology-Oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Fernando Cabanillas, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Auxilio Mutuo Cancer Center

Locations

Hospital Auxilio Mutuo Cancer Center

San Juan, Puerto Rico, Puerto Rico

Countries

Puerto Rico

Other Identifiers

CCAM 07

Identifier Type: -

Identifier Source: org_study_id